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Objective To compare the e¤cacy and tolerability ofmeropenem and imipenem/cilastatin as empirical
monotherapy in intensive care unit (ICU) patients with serious bacterial infections.
Methods Amulticenter, open-label, randomized, parallel-group trial was conducted in Belgium,
evaluating empirical monotherapywithmeropenemor imipenem/cilastatin (both1  g/8  h intravenously) in
ICUpatients with one or more of the following infections caused by sensitive pathogens: lower respiratory
tract infection (LRTI) in ventilated patients, intra-abdominal infection or sepsis.
Results The overall satisfactory clinical response rate at the end of randomized treatment was 77.0% (67/
87) withmeropenem and 68.1% (62/91) with imipenem/cilastatin (di¡erence 8.9%; 95% con¢dence
intervalÿ4.2% to 21.9%; P    0.185).The two drugs produced similar satisfactory clinical response rates
against LRTIs: 68.3% (41/60) withmeropenemversus 68.6% (35/51) with imipenem/cilastatin.
Meropenem appeared to be slightlymore e¡ective against intra-abdominal infections: 95.5% (21/22) versus
76.7% (23/30), respectively. All ¢vemeropenem recipients with sepsis had a satisfactory clinical response,
compared to 40.0% (4/10) of thosewho received imipenem/cilastatin.The overall satisfactory bacteriologic
response rate was 67.1% (49/73) withmeropenem and 60.3% (44/73) with imipenem/cilastatin (di¡erence
6.9%; 95% con¢dence intervalÿ8.7% to 22.4%; P    0.389).The predominant pathogenswere Escherichia
coli, Enterobacter spp. and Pseudomonas aeruginosa. No incidences of drug-related nausea and vomitingwere
reported, but one probable drug-related seizure occurred in the imipenem/cilastatin group.
Conclusions Meropenem is at least as e¤cacious (clinically and bacteriologically) as imipenem/cilastatin
for the empirical monotherapyof serious bacterial infections in ICUpatients, and it can therefore be
considered a useful option in this setting.Moreover, meropenem is well tolerated and o¡ers several potential
advantages, including greater in vitro activity against Gram-negative pathogens and the option of bolus
administration.
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I N T R O D U C T I O N
Serious bacterial infections are common in patients in the
intensive care unit (ICU) and they result in considerable mor-
bidity and mortality. Approximately 45% of the 10,038 ICU
patients included in the European Prevalence of Infection in
Intensive Care (EPIC) Survey of 1992 had at least one bacterial
infection [1]. Pneumonia and other lower respiratory tract
infections (LRTIs) were the most prevalent infections
(64.7%), followed by urinary tract (17.6%) and bloodstream
infections (12.0%).Themost frequently reported bacterial iso-
lates were Enterobacteriaceae (mainly Escherichia coli, Klebsiella
spp. and Enterobacter spp.), Staphylococcus aureus, Pseudomonas aer-
uginosa and coagulase-negative staphylococci. Fifty-¢ve per
cent of ICU-acquired infections were polymicrobial.
In this setting, empirical antibiotic treatmentmust therefore
have a broad spectrum of antibacterial activity, covering
Gram-positive and Gram-negative aerobes and anaerobes.
Traditionally, this has been achieved by using combinations of
antibiotics, usually a b-lactam agent (e.g. a third-generation
cephalosporin) plus an aminoglycoside or antianaerobic agent.
However, the usefulness of many b-lactams, including the
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third-generation cephalosporins, is threatened by the spread
of plasmid-mediated, extended-spectrum b-lactamases
(ESBLs) in Enterobacteriaceae [2]. Up to 23% of Klebsiella
isolates from European ICUs may produce these enzymes [3].
Furthermore, over-expression of inducible group I b-lacta-
mases by Enterobacter, Citrobacter, Serratia and Pseudomonas spp.
compromises the activity of cephalosporins and b-lactam/b-
lactamase inhibitor combinations, while constitutive hyper-
producers are readily selected during therapywith these agents
[4].
The carbapenems possess the widest antibacterial spectra
and greatest b-lactamase stability of all b-lactams, and there-
fore these agents o¡er a realistic option for monotherapy in
serious bacterial infections. The only two carbapenems avail-
able outside Japan, meropenem and imipenem/cilastatin, are
active against most clinically important pathogens and are
stable to the vast majority of serine-based b-lactamases
(including ESBLs and Bush Group I enzymes) [5, 6]. How-
ever, important di¡erences exist between the two compounds
[7], which may favor the use of meropenem in the ICU set-
ting.These include the greater in vitro activity of meropenem
against the predominant Gram-negative pathogens [5] and its
stability to renal dehydropeptidase-I (DHP-I), which permits
its administrationwithout a DHP-I inhibitor such as cilastatin
(which can accumulate in renal failure [8]). In addition, mero-
penem is well tolerated by the central nervous system (CNS)
with regard to seizures [7] and can be administered by bolus
intravenous injection.
This study compared the e¤cacy and tolerability of mero-
penem and imipenem/cilastatin as empirical monotherapy in
ICUpatients with serious bacterial infections.
M A T E R I A L S A N D M E T H O D S
This was a multicenter, open-label, randomized, parallel-
group trial conducted in Belgium to compare intravenous
meropenem and imipenem/cilastatin in ICU patients with
severe or life-threatening infections caused by sensitive patho-
gens.
Patients
These comprised ICU adults (aged r18  years) requiring par-
enteral antibacterial therapy for one or more of the following
infections: LRTI (in mechanically ventilated patients), intra-
abdominal infections and sepsis. For eligibility, at least one
responsible pathogen isolated at study entry had to be suscepti-
ble to both study drugs. In patients with multiple infection
sites, the most serious was designated as the primary site, and
additional sites were ranked in order of importance.This trial
gained local Ethics Committee approval, and informed con-
sent was obtained from all patients or their next of kin.
Patients were excluded if they were pregnant or breastfeed-
ing, if they had a hypersensitivity to any b-lactam, if they suf-
fered from hepatic impairment, neutropenia or cystic ¢brosis,
or if they had a history of CNS disease or other disorder likely
to cause convulsions. Patients with severe underlying disease
whowere unlikely to complete at least 48  h of study treatment
were excluded, as were those receiving probenecid. Patients
with secondary infections at sites other than those speci¢ed
above were also ineligible. Patients could only enter the trial
once.
Therapeutic regimen
Patients were randomized to receive either meropenemor imi-
penem/cilastatin, each administered intravenously at a dosage
of 1  g every 8  h. Randomizationwas strati¢ed according to the
three types of primary infection. Meropenem was adminis-
tered either as a bolus injection or as an infusion over a period
of 20^30  min. Imipenem/cilastatin was infused over 40^60  
min (or at a slower rate if the patient experienced nausea or
vomiting). Since both study drugs are chie£y eliminated ren-
ally, their dosages were adjusted according to the degree of
renal impairment. An additional dose of study drug was given
after hemodialysis.The recommended duration of therapywas
5^10  days (maximum 28  days). Treatment for a minimum of
48  hwas required for the assessment of e¤cacy. No other anti-
bacterials were allowed during the study, except in the event
of surgical prophylaxis or treatment failure.
Clinical assessment
The overall condition of the patient at entry was assessed
using the Acute Physiology and Chronic Health Evaluation
(APACHE II) scoring system [9]. Clinical signs and symptoms
associatedwith infectionwere evaluatedwithin 3  days prior to
commencing treatment and daily during treatment.
Sepsis was de¢ned as a clinical entity characterized by one
or more of the following signs and symptoms [10]: fever (>  
38.3  C), chills, leukocytosis, hyperventilation, hypothermia,
skin lesions, septic embolism, change in mental status, hypo-
tension, disseminated intravascular coagulation (DIC) and
organ failure.
Intra-abdominal infections were described as either
abscesses or peritonitis originating from the following intra-
abdominal organs: stomach, duodenum, biliary tract, pan-
creas, appendix, small intestine and colon.
For LRTI to be diagnosed, the following signs and symp-
toms had to be present: pulmonary in¢ltration thought to be
due to infection on chest X-ray and at least two of the follow-
ing criteriaöpurulent sputum (<  10 squamous epithelial
cells,  >  25 white blood cells, and a pathogen should be cul-
tured), fever and leukocytosis. The respiratory sample should
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be obtained by endotracheal aspirate, bronchoalveolar lavage,
protected specimen brush, pleural £uid or lung biopsy.
Hospital-acquired infections were de¢ned as late-onset
infections (>  72  h) or any postoperative infections, whereas
community-acquired infectionswere of earlyonset (<  72  h).
The clinical response was assessed at the end of treatment
or at the time when additional antibiotics or antifungals were
added in the event of treatment failure and/or upon the devel-
opment of new infections or superinfections. Clinical
response was classi¢ed as cured (complete remission of local
and systemic signs and symptoms), improved (improvement
of local and systemic signs and symptoms but without com-
plete resolution) or unchanged/worse (no improvement or
deterioration of signs and symptoms). If relevant, clinical
response was reassessed at a follow-up examination 2^4  weeks
post-treatment. At follow-up, clinical response could also be
classi¢ed as relapse (initial cure/improvement followed by a
general decline andworsening of the clinical condition).
The clinical response was considered satisfactory if the
patient was cured or improved, and unsatisfactory if the
patient was unchanged/worse or experienced a relapse.
The tolerability of the studydrugs was assessed by monitor-
ing adverse events and routine clinical laboratory tests.
Bacteriologic assessment
Cultures were obtained from sites appropriate to the infection
immediately (or within 3  days) prior to starting treatment,
during treatment if clinically indicated, preferably immedi-
ately after study treatment was discontinued or changed, and
at 2^4  weeks follow-up, if possible.
Acceptable specimens from patients with intra-abdominal
infections included peritoneal £uid, drain £uid, abscess mate-
rial or pus. For patients with LRTI, endotracheal aspirates,
bronchoalveolar lavage or protected specimen brush samples,
abscess material, pleural £uid and hemocultures or blood cul-
tures were accepted.Twoblood cultures, preferably from sepa-
rate sites or from an intra-arterial line (taken at least 30  min
apart), were collected before treatment from patients with sus-
pected sepsis. Susceptibility testing was performed according
to standard accepted disk sensitivity criteria [11].
Disks loaded with meropenem (10  mg) or Rosco tablets of
meropenem were provided by AstraZeneca Pharmaceuticals
for sensitivity testing using Kirby^Bauer (or equivalent)
determinations. Commercially available disks or tablets were
used for sensitivity testing of imipenem for assessment of
comparative activity.
Resistance to meropenem was de¢ned as a zone size of
R11  mm, and resistance to imipenem as a zone size of R13  
mm (R13  mmandR16  mm, respectively, forRosco tablets).
The bacteriologic response was assessed at the end of the
therapy (or at the time when additional antibiotics were given
for treatment failure or new infections) and at follow-up, if
possible.
The response was considered satisfactory when the original
pathogen(s) were eradicated or presumed eradicated (i.e. when
further sampling was not considered justi¢ed because of clini-
cal cure/improvement). The response was considered unsatis-
factory if the primary pathogen persisted (or was presumed to
have persisted) or if a new pathogen isolated at the original
infection site during study therapy required antibacterial
treatment (i.e. superinfection occurred). At follow-up, the
bacteriologic response could also be classi¢ed as relapse.
Statistical methods
The primary endpoint was the percentage of patients in each
treatment groupwith a satisfactory clinical response at the end
of randomized treatment. A satisfactory response rate of 85%
was assumed for imipenem/cilastatin.To demonstrate equiva-
lence between meropenem and imipenem/cilastatin, the
upper 95% con¢dence interval (CI) (a  0.05) for the di¡er-
ence between response rates was not to exceed 15%. In order
to ensure a power of 80% (b    0.20), 90 fully evaluable
patients were required in each group. Since only 85% of ran-
domized patients were expected to be evaluable for response,
we aimed to recruit a total of approximately 210 patients.
Secondary endpoints included the satisfactory clinical
response rate at the end of treatment in bacteriologically eva-
luable patients, and the bacteriologic response at the end of
treatment for evaluable patients. In addition, a subgroup ana-
lysis according to the type of infectionwas performed.
For each endpoint, the proportions of patients with a satis-
factory response in each group were compared using a chi-
square test. The di¡erence in proportions was estimated,
together with 95% CI (calculated using a normal approxima-
tion), and statistical signi¢cance determined using the chi-
square test.
R E S U L T S
Patients
Atotal of 212 patients entered the study,107 in the meropenem
group and 105 in the imipenem/cilastatin group. The demo-
graphic and baseline clinical characteristics of the two groups
were similar (Table  1). The mean APACHE II score was
slightly higher in the meropenem group than in the imipe-
nem/cilastatin group, as was the number of patients who had
received previous antibacterial therapy. The majority of
patients (66.9%) were mechanically ventilated. LRTI was the
most common infection diagnosis, followed by intra-abdom-
inal infection and sepsis. The mean (þ Standard Deviation
(SD)) durations of treatment in the meropenem and imipe-
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nem/cilastatin groups were 9.8  þ  4.9  days and 9.8  þ  5.3  days,
respectively. Almost 60% of the meropenem patients received
drug by bolus injection.
Twenty patients were excluded from the analysis due to
protocol violations (Figure 1), leaving 192 evaluable patients
(94 meropenem, 98 imipenem/cilastatin). Of these, 178 (87
meropenem, 91 imipenem/cilastatin) were evaluable for clini-
cal response at the end of treatment, and 146 (73 meropenem,
73 imipenem/cilastatin) were evaluable for bacteriologic
response at the end of treatment.The reasons for clinical non-
evaluability are outlined in Figure1.
Ef®cacy
Among evaluable patients, the overall satisfactory clinical
response rates at the end of randomized treatment were 77.0%
(67/87) in themeropenemgroup and 68.1% (62/91) in the imi-
penem/cilastatin group (di¡erence 8.9%; 95% CI ÿ4.2% to
21.9%; P    0.185). Meropenem and imipenem/cilastatin pro-
duced similar satisfactory clinical response rates against
LRTIs, while meropenem appeared to be slightly more e¡ec-
tive against intra-abdominal infections (Table  2). All ¢ve
patients with sepsis treatedwith meropenem had a satisfactory
clinical response, compared with 40.0% (4/10) of those in the
imipenem/cilastatin group (Table  2).
The overall satisfactory clinical response at the end of treat-
ment in bacteriologically evaluable patients was 76.7% (56/73)
in the meropenem group and 72.6% (53/73) in the imipenem/
cilastatin group.The respective response rates for meropenem
and imipenem/cilastatin in the following infections were
69.2% (36/52) and 73.8% (31/42) for LRTI, 94.4% (17/18) and
82.6% (19/23) for intra-abdominal infections, and 100% (3/3)
and 37.5% (3/8) for sepsis.
The overall satisfactory bacteriologic response rates at the
end of treatment were 67.1% (49/73) in the meropenem group
and 60.3% (44/73) in the imipenem/cilastatin group (di¡er-
ence 6.9%; 95% CI, ÿ8.7% to 22.4%; P    0.389). The two
drugs showed similar bacteriologic e¤cacy against LRTIs and
intra-abdominal infections, although meropenem produced a
higher response rate in the small number of patients with sep-
sis (Table  2).
Similar percentages of isolated pathogens were eradicated
(or presumed to be eradicated) bymeropenem (88/108; 81.5%)
and imipenem/cilastatin (94/128; 73.5%). The predominant
pathogens were Enterobacteriaceae (Table  3), against which
meropenem appeared to be slightlymore e¡ective than imipe-
nem/cilastatin.
Table  1 Demographic and baseline clinical characteristics of clinically evaluable patients
Meropenem Imipenem/cilastatin
Criteria (n    87) (n    91)
Gender (M/F) 59/28 59/32
Mean age (years) [range] 64.2 [20±87] 56.4 [6±87]
Aged r65  years 57 (65.5%) 48 (52.7%)
Mean APACHE II score (standard deviation) 18.4 (8.6) 15.7 (8.1)
APACHE II score
0±10 9 (10.3%) 18 (19.8%)
11±20 43 (49.4%) 46 (50.5%)
21±30 24 (27.6%) 23 (25.3%)
>  31 8 (9.2%) 4 (4.4%)
Not recorded at study entry 3 (3.4%) 0 (0.0%)
Previous antibiotic therapy 56 (64.4%) 46 (50.5%)
Mechanically ventilated 63 (72.4%) 56 (61.5%)
Recent surgery 20 (23.0%) 27 (29.7%)
Active neoplasm 4 (4.6%) 4 (4.4%)
Primary infection diagnosis
Lower respiratory tract 60 (69.0%) 51 (56.0%)
Pneumonia 49 (56.3%) 37 (40.7%)
Intra-abdominal 22 (25.3%) 30 (33.0%)
Peritonitis 19 (21.8%) 23 (25.3%)
Abscess 4 (4.6%) 11 (12.1%)
Sepsis 5 (5.7%) 10 (11.0%)
Primary infection source
Hospital 69 (79.3%) 64 (70.3%)
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Bacterial superinfection occurred in nine bacteriologically
evaluable meropenem recipients and 11 of those who received
imipenem/cilastatin (Table  4).
Safety and tolerability
Both drugs were well tolerated. In the meropenem group, 66
adverse events were reported in 50 patients (46.7%), whereas
60 adverse events were noti¢ed in 44 patients (41.9%) treated
with imipenem/cilastatin. Adverse events considered to be
related to the study drug were reported in 3.7% (4/107) of
patients treated with meropenem and 2.9% (3/105) of those
who received imipenem/cilastatin. No incidences of drug-
related nausea and vomiting were reported in either group,
but one probable drug-related seizurewas reported in a patient
treatedwith imipenem/cilastatin.
Figure  1 Summary of patient numbers and reasons for exclusion/non-evaluability.aReasons for protocol violations necessitating
exclusion from analysis: secondary infections (two patients with skin/skin structure infections and three with urinary tract infec-
tions), concomitant antibiotics at entry (6), fever of unknown origin at entry (1), and no ventilatory support LRTI patients (1) in the
meropenem group; and secondary infection (2 patients with skin/skin structure infections), concomitant antibiotics at entry (3),
fever of unknown origin at entry (1), and no ventilatory support LRTI patients (1) in the imipenem/cilastatin group.
bReasons for clinical non-evaluability: death during therapy (2 patients),  <  48  h monotherapy (2), known resistant pretherapy
pathogens (1), amoebic infection (1), and vancomycin added for superinfection (1) in the meropenem group; and <48  h monother-
apy (5, of which 3 were due to death), known resistant pretherapy pathogens (1) and incorrect treatment regimen (1 day of mero-
penem) (1) in the imipenem/cilastatin group.
Table  2 Satisfactory clinical and bacteriologic response rates at end of treatment in evaluable patients
Response ratea Meropenem Imipenem/cilastatin
Clinical
Overall 77.0% (67/87) 68.1% (62/91)
Lower respiratory tract infection 68.3% (41/60) 68.6% (35/51)
Intra-abdominal infection 95.5% (21/22) 76.7% (23/30)
Sepsis 100.0% (5/5) 40.0% (4/10)
Bacteriologic
Overall 67.1% (49/73) 60.3% (44/73)
Lower respiratory tract infection 61.5% (32/52) 57.1% (24/42)
Intra-abdominal infection 77.8% (14/18) 69.6% (16/23)
Sepsis 100.0% (3/3) 50.0% (4/8)
aPercentages of patients cured or improved (clinical) or with pathogens eradicated or presumed eradicated (bacteriologic).
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Table  3  Organism eradication and presumed eradication rates at end of treatment according to causative pathogen
Clinical isolate
Eradicated/total
Meropenem
Eradicated/total
Imipenem/cilastatin
Gram-negative aerobes
Escherichia coli 14/17 13/20
Enterobacter spp. 11/13 6/14
Pseudomonas aeruginosa 7/10 5/10
Klebsiella pneumoniae 6/6 3/3
Proteus mirabilis 7/7 0/2
Haemophilus spp. 2/2 5/5
Morganella morganii 1/1 5/7
Acinetobacter spp. 2/5 4/7
Serratia marcescens 2/2 4/5
Klebsiella oxytoca 1/1 3/4
Citrobacter freundii 1/1 2/3
Proteus vulgaris 1/2 ±
Others 4/5 4/6
Total 59/72 (81.9%) 54/86 (62.8%)
Gram-positive aerobes
Staphylococcus aureus 6/10 6/6
Enterococcus spp. 4/6 7/8
Others 11/12 10/10
Total 21/28 (75.0%) 23/24 (95.8%)
Anaerobes
Total 8/8 (100.0%) 17/18 (94.4%)
All clinical isolates 88/108 (81.5%) 94/128 (73.5%)
Table  4  Superinfections and colonizations that occurred in bacteriologically evaluable patients
Organisms
Meropenem (n  =  73) Imipenem/cilastatin (n  =  73)
No. of patients with
superinfection
No. of patients with
colonizationa
No. of patients
with superinfection
No. of patients with
colonizationa
Gram-negative aerobes
Enterobacter cloacae ± ± 1 0
Proteus mirabilis ± ± 2 5
Providencia stuartii ± ± 1 0
Pseudomonas aeruginosa 2 1 4 0
Stenotrophomonas maltophilia 1 3 0 1
Total 3 4 8 6
Gram-positive aerobes
Corynebacterium xerosis 1 0 ± ±
Enterococcus faecalis 0 2 0 1
Methicillin-resistant
Staphylococcus aureus
2 0 ± ±
Staphylococcus epidermidis 3 6 3 3
Staphylococcus spp. ± ± 0 3
Total 6 8 3 7
Fungi/yeasts
Aspergillus spp. ± ± 0 1
Candida albicans 3 4 2 2
Candida spp. 1 1 1 1
Yeast (unspeci®ed) 0 1 1 0
Total 4 6 4 4
aColonization = any new organism isolated at the primary site but not requiring any additional antimicrobial therapy.
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There were nine deaths during therapy in the meropenem
group (8.4% of recruited patients) and 14 (13.3%) in the imi-
penem/cilastatin group.
In the meropenem group there were six deaths (6/9;
66.7%) considered to be probably or possibly related to infec-
tion, versus 10 (10/14; 71.4%) in the imipenem/cilastatin
group.
No deaths in either treatment group were considered to be
related to study therapy. Death appeared to be related to pre-
therapyAPACHE II score, although the data are limited by the
small numbers of patients involved [9].
During the follow-up period, after the end of treatment,
there were 22 deaths (20.6%) in the meropenem group and 14
in the imipenem/cilastatin group (13.3%). None of these
deaths was considered to be drug-related. As most patients at
this stage of their critical illness are heavily colonized and/or
infected in one or several organ systems, it seems hazardous to
directly attribute death to infection.
In the meropenem group, six deaths (27.3%) were probably
not infection-related (acute vascular injury (n    1), cardiac
arrest (n    1), brain damage (n    2), withdrawal of all therapy
(n    2)); four deaths (18.1%) were probably infection-related
(refractory septic shockötwowithin 3  days post trial); and 12
deaths (54.6%) were possibly infection-related (single organ
failureöacute respiratory distress syndrome (ARDS), acute
renal failure (ARF)öormultiple organ failure (MOF)).
In the imipenem group, six deaths (42.9%) were probably
not related to infection (cerebral damage (n    1), cardiac arrest
(n    2), acute respiratory failure (n    3)); three deaths (21.4%)
were probably infection-related (refractory septic shocköall
within 5  days post trial); and ¢ve deaths (35.7%) were possibly
related to infection (ARDS,MOF).
D I S C U S S I O N
Meropenem monotherapy (1  g/8  h) has been shown to be at
least as e¤cacious as combination antibacterial therapy in the
treatment of a variety of infections, including nosocomial
LRTI [12], intra-abdominal infection [13, 14] and sepsis [15].
Previous randomized studies have shown meropenem and
imipenem/cilastatin to be similarly e¤cacious at this dosage
for the empirical treatment of serious infections in ICU
patients [16^18].
In the present study, meropenem produced a slightly higher
overall satisfactory clinical response than imipenem/cilastatin
(77.0% versus 68.1%), although the di¡erence did not reach
statistical signi¢cance. This ¢nding does not appear to be
related to any di¡erence between the patients in the two
groups. Rather, analysis of the infection subgroups indicates
that apparent di¡erences between the drugs in terms of their
e¤cacy against intra-abdominal infection and sepsis were
responsible for the slightly better overall satisfactory response
rate with meropenem. However, the number of patients in
some infection subgroups was small, particularly for those
with sepsis.
The most common infection diagnosis was LRTI, and all
of these patients were mechanically ventilated. Pneumonia is
the hospital-acquired infection most likely to lead to the death
of critically ill patients [19, 20]. Controversy remains about the
most accurate way to diagnose this infection and the appropri-
ate timing of antibiotic therapy in relation to the clinical suspi-
cion of pneumonia [21]. Of all bronchoscopic and non-
bronchoscopic diagnostic tests, endotracheal aspirate culture
might be the most practical, andwas mostly used in this study.
Additional research is needed to determine the applicability of
other diagnostic procedures in daily clinical practice. Some
studies have shown that antibiotic therapy may have a favor-
able impact on the outcome of pneumonia, with lower mor-
tality rates being observed if appropriate therapy is prescribed
[22^24]. Recent trials have con¢rmed that timely and appro-
priate empirical antibiotic therapy is crucial and can improve
survival in patients with pneumonia [25, 26]. The two carba-
penems proved similarly e¤cacious in these patients. Interest-
ingly, another recent study performed in seriously ill patients
[18] noted a slightly better response rate with meropenem
compared to imipenem/cilastatin in patients with nosocomial
LRTIs (89% versus 76%). Unlike in the present study, how-
ever, not all patients with LRTIs in the studyof Garau et al [18]
were mechanically ventilated, which may explain the di¡er-
ence in response rates. The severity of the underlying disease
and acute illness of the a¡ected patients largely account for the
poor outcome in the present study. Most infections are caused
by Gram-negative bacilli, especially Pseudomonas species, and
up to 55% of cases are caused by polymicrobial infection [27].
Prior antimicrobial therapy is a risk factor both for pneumonia
and for infections with di¤cult-to-treat organisms, leading to
poor response to therapy and a poor outcome [28].
Di¡erences between treatment groups in the satisfactory
bacteriologic response rates generally mirrored the clinical
¢ndings, with meropenem proving at least as e¤cacious as
imipenem/cilastatin overall and for each infection subgroup.
Eradication rates according to pathogen were generally as
would be predicted from the in vitro spectra of the two carba-
penems. Notable di¡erences, however, were the apparently
more favorable results with meropenem against important
Gram-negative ICU pathogens, particularly Escherichia coli,
Enterobacter spp. and Pseudomonas aeruginosa. According to a
similar study, both meropenem and imipenem/cilastatin
proved highly e¡ective against the anaerobes, while a some-
what higher eradication rate of Gram-positive aerobes was
observed in the imipenem/cilastatin group [16].
Both drugs were well tolerated with regard to serious
adverse events. The risk of seizures is a concern with higher
doses of imipenem/cilastatin, especially in the presence of
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impaired renal function and/or CNS disease [29]. However,
patients with CNS disease were excluded from this study, and
dosage reduction was performed according to the degree of
renal impairment. This may explain why only one probable
drug-related seizure was reported with imipenem/cilastatin.
This compares with a seizure rate of 6% of patients receiving
the same dosage of imipenem/cilastatin for the treatment of
severe pneumonia [30].The absence of seizures with merope-
nem is in line with the documented low seizurogenic activity
of this agent in animal studies [31, 32] and in clinical trials that
used doses up to 6  g/day [7], some of which included patients
withmeningitis [33, 34].
No drug-related instances of nausea or vomiting were
reported in this study. Previous studies, mostly (but not exclu-
sively) in neutropenic patients, have found nausea and vomit-
ing to be a problem with imipenem/cilastatin [35^39]. In
contrast, nausea and vomiting is not a signi¢cant problem
with meropenem, even after bolus administration of the drug
[7]. This adverse e¡ect, which appears to be related to the
dosage and rate of infusion of imipenem/cilastatin [35, 40],
was avoided in this study by administering this agent slowly
over 40^60  min. Meropenem was administered by bolus
injection in almost 60% of patients in the present study. The
option of bolus administration is particularly useful in ICU
patients, in whom renal failure and left ventricular failure are
common and £uid overload/hypervolemiamust be avoided.
In summary, meropenem is at least as e¤cacious (clinically
and bacteriologically) as imipenem/cilastatin for the empirical
monotherapy of serious bacterial infections in ICU patients,
and it can therefore be considered a useful option in this set-
ting. Moreover, meropenem is well tolerated and o¡ers several
potential advantages over imipenem/cilastatin, including
greater in vitro activity against Gram-negative pathogens and
the option of bolus administration.
A C K N O W L E D G M E N T S
This workwas presented in part at the17th International Sym-
posium on Intensive Care and Emergency Medicine, Brussels,
Belgium,18^21March1997, and at the 8th European Congress
of Clinical Microbiology and Infectious Diseases, Lausanne,
Switzerland, 25^28 May 1997.The Belgian Multicenter Study
Group comprised the following (number of patients
enrolled): M. Aoun, Brussels (3); J. Bockaert, Mechelen (7); F.
Colardyn, Gent (22); R. De Jongh, Genk (5); G.Willems, B.
De Waele, Brussels (9); M. Genard, Mons (12); G. Huylen-
broeck, Aalst (7); E. Installe¨, Mont-Godinne (7); P. Jamaer,
Hasselt (3); L. Janssen, Geel (28); M. Laurent, La Louvie© re (2);
P. Lauwers, Leuven (40); J. C. Legrand, Charleroi (18); H. Les-
sire, Brussels (22); D. Noirot, P. Paris, Lie© ge (9); G. Nollet, J.
Verbeke, Aalst (18).
Our thanks also go toThierryVan Hedent, Steven Huysse,
Geert Byttebier, Freya De Beurme, Peggy Van Wijmeersch,
Philippe Peeters, Hilde De Roeck and Kristof Daems, (Astra-
Zeneca, Brussels, Belgium) for their logistic support.
This study was supported by a grant from AstraZeneca
Pharmaceuticals.
R E F E R E N C E S
1. Vincent JL, Bihari DJ, Suter PM et al.The prevalence of nosoco-
mial infection in intensive care units in Europe. Results of the
European Prevalence Infection Intensive Care (EPIC) Study.
JAMA1995; 274: 639^44.
2. Sirot D. Extended spectrum plasmid-mediated b-lactamases. J
AntimicrobChemother1995; 36(suppl A): 19^34.
3. Livermore DM,Yuan M. Antibiotic resistance and production of
extended-spectrum b-lactamases amongst Klebsiella spp. from
intensive care units in Europe. J Antimicrob Chemother 1996; 38:
409^24.
4. Sanders CC, SandersWE. b-lactam resistance in Gram-negative
bacteria: global trends and clinical impact. Clin Infect Dis 1992; 15:
824^39.
5. Edwards JR. Meropenem: a microbiological overview. J Antimi-
crobChemother1995; 36(suppl A): 1^17.
6. Balfour JA, Bryson HM, Brogden RN. Imipenem/cilastatin: an
update of its antibacterial activity, pharmacokinetics and thera-
peutic e¤cacy in the treatment of serious infections. Drugs 1996;
51: 99^136.
7. Norrby SR, Gildon KM. Safety pro¢le of meropenem: a review
of nearly 5000 patients treated with meropenem. ScandJ Infect Dis
1999; 31(1): 3^10.
8. Verpooten GA,Verbist L, Buntinx AP, Entwistle LA, Jones KH,
De Broe ME.The pharmacokinetics of imipenem (thienamycin-
formanmidine) and the renal dehydropeptidase inhibitor cilasta-
tin sodium in normal subjects and patients with renal failure. BrJ
Clin Pharmacol1984;18: 183^93.
9. Knaus WA, Draper EA,Wagner DP, Zimmerman JE. APACHE
II: a severity of disease classi¢cation system.Crit CareMed1985;13:
818^29.
10. Bone RC, Sprung CL, Sibbald WJ. De¢nitions for sepsis and
organ failure.CritCareMed1992; 20(6): 724^6.
11. National Committee for Clinical Laboratory Standards. Perfor-
mance standards for antimicrobial disk susceptibility tests, 4th edn.
Approved StandardM2-A4.Villanova: NCCLS,1990.
12. Sieger B, Berman SJ, Geckler RW, Farkas SA, for the Meropenem
Lower Respiratory Infection Group. Empiric treatment of hospi-
tal-acquired lower respiratory tract infections withmeropenemor
ceftazidime with tobramycin: a randomized study. Crit Care Med
1997; 25: 1663^70.
13. Condon RE, Walker AP, Sirinek KR et al. Meropenem versus
tobramycin plus clindamycin for treatment of intraabdominal
infections: results of a prospective, randomized, double-blind
clinical trial.Clin InfectDis1995; 21: 544^50.
14. HuizingaWKJ,Warren BL, Baker P et al.Antibiotic monotherapy
with meropenem in the surgical management of intra-abdominal
infections. JAntimicrobChemother1995; 36(suppl A): 179^89.
15. Solberg CO, Sjursen H. Safety and e¤cacy of meropenem in
patients with septicaemia: a randomised comparisonwith ceftazi-
dime, alone or combined with amikacin. J Antimicrob Chemother
1995; 36(suppl A): 157^66.
âò"Verwaest Meropenem versus imipenem/cilastatin in serious infections
= 2000 Copyright by the European Society of Clinical Microbiology and Infectious Diseases, CMI, 6, 294±302
16. Colardyn F, Faulkner KL, on behalf of the Meropenem Serious
Infection Study Group. Intravenous meropenem versus imipe-
nem/cilastatin in the treatment of serious bacterial infections in
hospitalized patients. JAntimicrobChemother1996; 38: 523^37.
17. Hartenauer U, Kljucar S, Bender HJ, Weilemann S, Nusser H,
Bodmann KF. Meropenem versus imipenem/cilastatin for the
treatment of serious bacterial infections at ICU. Antiinfect Drugs
Chemother1997;15: 65^70.
18. Garau J, Blanquer J, Cobo L et al. Prospective, randomised, multi-
centre study of meropenemversus imipenem/cilastatin as empiric
monotherapy in severe nosocomial infections. Eur J Clin Microbiol
InfectDis1997;16: 789^96.
19. Niederman MS, Craven DE, Fein AM, Schultz DE. Pneumonia
in the critically ill hospitalized patient.Chest1990; 97(1): 170^81.
20. Fagon JY, Chastre J, Hance AJ, Montravers P, Novara A, Gibert
C. Nosocomial pneumonia in ventilated patients: a cohort study
evaluating attributable mortality and hospital stay. AmJMed1993;
94: 281^8.
21. Fagon JY, Chastre J, Domart Y et al. Nosocomial pneumonia in
patients receiving continuous mechanical ventilation. Am Rev
RespirDis1989;139: 877^84.
22. Celis R, Torres A, Gatell JM, Almela M, Rodriguez-Roisin R,
Agusti-Vidal A. Nosocomial pneumonia. A multivariate analysis
of risk and prognosis.Chest1988; 93 (2): 318^24.
23. Torres A, Aznar R, Gatell JM et al. Incidence, risk, and prognosis
factors of nosocomial pneumonia in mechanically ventilated
patients.AmRevRespirDis1990;142(3): 523^8.
24. Alvarez-Lerma F. Modi¢cation of empiric antibiotic treatment in
patients with pneumonia acquired in the intensive care unit. ICU-
Acquired Pneumonia Study Group. Intensive CareMed1996; 22(5):
387^94.
25. Luna CM,Vujacich P, Niederman MS et al. Impact of BAL data
on the therapy and outcome of ventilator-associated pneumonia.
Chest1997;111(3): 676^85.
26. Kollef MH, Sherman G,Ward S, FraserVJ. Inadequate antimicro-
bial treatment of infections: a risk factor for hospital mortality
among critically ill patients.Chest1999;115(2): 462^74.
27. Rello J, Quintana E, AusinaVet al. Incidence, etiology, and out-
come of nosocomial pneumonia in mechanically ventilated
patients.Chest1991;100(2): 439^44.
28. Kollef MH, Silver P, Murphy DM, Trovillion E. The e¡ect of
late-onset ventilator-associated pneumonia in determining
patient mortality.Chest1995;108(6): 1655^62.
29. Calandra G, Lydick E, Carrigan J,Weiss L, Guess H. Factors pre-
disposing to seizures in seriously ill infected patients receiving
antibiotics: experience with imipenem/cilastatin. AmJ Med 1988;
84: 911^18.
30. Fink MP, Snydman DS, Niederman MS et al.Treatment of severe
pneumonia in hospitalized patients: results of a multicenter, ran-
domized double-blind trial comparing intravenous cipro£oxacin
with imipenem/cilastatin. Antimicrob Agents Chemother 1994; 38:
547^57.
31. Patel JB, Giles RE.Meropenem: evidence of lackof proconvulsive
tendency in mice. J Antimicrob Chemother 1989; 24(suppl A): 307^
9.
32. De Sarro A, Ammendola D, Zappala M, Grasso S, De Sarro GB.
Relationship between structure and convulsant properties of
some b-lactam antibiotics following intracerebroventricular
microinjection in rats. Antimicrob Agents Chemother 1995; 39: 232^
7.
33. Schmutzhard E,Williams KJ,Vukmirovits G et al. A randomised
comparison of meropenemwith cefotaxime or ceftriaxone for the
treatment of meningitis in adults. J Antimicrob Chemother 1995;
36(suppl. A): 85^98.
34. Klugman KP, Dagan R, the Meropenem Meningitis Study
Group. A randomised comparison of meropenem with cefotax-
ime for the treatment of bacterial meningitis. Antimicrob Agents
Chemother1995; 39: 1140^6.
35. Norrby SR,VandercamB, LouieT. Imipenem/cilastatin vs amika-
cin plus piperacillin in the treatment of infections in neutropenic
patients: a prospective, randomized, multi-clinic study. Scand J
InfectDis Suppl1987; 52: 65^78.
36. Winston DJ,Winston G, Bruckner DA, Champlin RE. Beta-lac-
tam antibiotic therapy in febrile granulocytopenic patients. Ann
InternMed1991;115: 849^59.
37. Freifeld AG,WalshT, Marshall Tet al.Monotherapy for fever and
neutropenia in cancer patients: a randomized comparison of cefta-
zidime versus imipenem. JClinOncol1995;13: 165^76.
38. Norwegian Study Group. Imipenem/cilastatin as monotherapy
in severe infections: comparison with cefotaxime in combination
with metronidazole and cloxacillin. Scand J Infect Dis 1987; 19:
667^75.
39. Mandell LA,Turgeon PL, Ronalds AR, Canadian Trials Group.
A prospective randomized trial of imipenem/cilastatin vs. clinda-
mycin-tobramycin in the treatment of intra-abdominal and pelvic
infections.CanJ InfectDis1993; 4: 279^87.
40. Wang C, Calandra GB, Aziz MA, Brown KR. E¤cacy and safety
of imipenem/cilastatin: a review of world-wide clinical experi-
ence.Rev InfectDis1985; 7(suppl 3): 528S^36S.
âòá Clinical Microbiology and Infection, Volume 6 Number 6, June 2000
= 2000 Copyright by the European Society of Clinical Microbiology and Infectious Diseases, CMI, 6, 294±302
